Regeneron Pharmaceuticals Inc. buy Citigroup Inc.
Summary
This prediction is currently active. The prediction currently has a performance of 13.34%. Dividends of €0.88 are taken into consideration when calculating the performance. This prediction currently runs until 29.10.26. The prediction end date can be changed by Citigroup_Inc_ at any time. Citigroup_Inc_ has 50% into this predictionRegeneron Pharmaceuticals, Inc. is a biotechnology company that is engaged in the discovery, development, and commercialization of medicines for the treatment of serious medical conditions. The company's products include EYLEA, a treatment for wet age-related macular degeneration and diabetic macular edema; Dupixent, a treatment for atopic dermatitis and asthma; and Libtayo, a treatment for certain types of cancer. Regeneron also has a strong focus on research and development, with a pipeline of potential new treatments for a variety of diseases. The company is headquartered in Tarrytown, New York and trades on the NASDAQ stock exchange under the symbol REGN.
Performance without dividends (%)
| Name | 1w | 1m |
|---|---|---|
| Regeneron Pharmaceuticals Inc. | 3.683% | 3.683% |
| iShares Core DAX® | -0.121% | 2.507% |
| iShares Nasdaq 100 | 0.081% | -0.241% |
| iShares Nikkei 225® | -1.748% | 4.105% |
| iShares S&P 500 | -0.961% | -0.143% |
Comments by Citigroup_Inc_ for this prediction
In the thread Regeneron Pharmaceuticals Inc. diskutieren
Stopped prediction by Citigroup_Inc_ for Regeneron Pharmaceuticals Inc.
Regeneron Pharmaceuticals Inc.
13.10.25
13.10.26
13:28
Regeneron Pharmaceuticals Inc.
02.06.25
02.06.26
13:28
Regeneron Pharmaceuticals Inc.
14.05.25
14.05.26
13:28

